IDRX-42 — Investigational Agent
KIT Inhibitor · Phase 3 · IDRx (GSK)
Mechanism of Action
Highly selective KIT tyrosine kinase inhibitor designed for potent activity against both activating exon 11/9 mutations and the exon 17/18 activation-loop resistance mutations, aiming to comprehensively suppress KIT-driven GIST including on-treatment resistance clones.
Investigational Indications
- Advanced/metastatic gastrointestinal stromal tumor (GIST)